Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00090493 · ClinicalTrials.gov registry record · Phase 2

Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma

A Phase 2 study of Multiple Myeloma, sponsored by University of Arkansas.

Completed
Registry status
Phase 2
Development phase
4
Enrollment target
1
Study location

NCT00090493 is a Phase 2 study of Multiple Myeloma that has completed, run by University of Arkansas. The registered enrollment target is 4 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00090493, a Phase 2 study of Multiple Myeloma, has completed, sponsored by University of Arkansas.

COMPLETED
Registry status
Phase 2
Development phase
4 participants
Enrollment target
1
Study location

Study Summary

The hope is that the peptide vaccines will stimulate the immune system to attack and kill the myeloma cells. The purpose is to generate anti-myeloma T-cells which will kill myeloma cells and nothing else.

Conditions Studied

Multiple Myeloma

Interventions

  • BIOLOGICAL MAGE-A3
  • BIOLOGICAL MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY

Study Locations (1)

Arkansas

  • University of Arkansas for Medical Sciences/MIRT - Little Rock

Trial Details

FieldValue
Enrollment Target 4 participants
Start Date 2004-06
Est. Completion 2012-05
Phase Phase 2

Sponsor

University of Arkansas

318 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00090493

The ClinicalTrials.gov registry entry for NCT00090493 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (99% lower). The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which MAGE-A3 is the first listed.

NCT00090493 reports 1 study location spanning 1 distinct geographic area - top geographies include Arkansas.

Frequently Asked Questions

What is clinical trial NCT00090493 about?

NCT00090493 is a clinical study titled "Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma". The hope is that the peptide vaccines will stimulate the immune system to attack and kill the myeloma cells. The purpose is to generate anti-myeloma T-cells which will kill myeloma cells and nothing else.

What is the current status of trial NCT00090493?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2004-06. Estimated completion is 2012-05.

What conditions does trial NCT00090493 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT00090493?

The interventions under investigation include: MAGE-A3 (BIOLOGICAL), MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY (BIOLOGICAL).

Who is sponsoring clinical trial NCT00090493?

This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00090493 being conducted?

This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.